Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Lifecome Biochemistry Co.,Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥13.27 |
52 Week High | CN¥33.00 |
52 Week Low | CN¥12.03 |
Beta | 0.72 |
11 Month Change | 1.30% |
3 Month Change | -20.40% |
1 Year Change | -56.29% |
33 Year Change | 22.19% |
5 Year Change | -13.22% |
Change since IPO | -21.19% |
Recent News & Updates
Benign Growth For Lifecome Biochemistry Co.,Ltd. (SZSE:002868) Underpins Stock's 26% Plummet
Apr 21Lifecome Biochemistry Co.,Ltd. (SZSE:002868) Stock Rockets 30% As Investors Are Less Pessimistic Than Expected
Mar 06Shareholder Returns
002868 | CN Biotechs | CN Market | |
---|---|---|---|
7D | 1.9% | -1.4% | -1.6% |
1Y | -56.3% | -22.6% | -19.6% |
Return vs Industry: 002868 underperformed the CN Biotechs industry which returned -22.6% over the past year.
Return vs Market: 002868 underperformed the CN Market which returned -19.6% over the past year.
Price Volatility
002868 volatility | |
---|---|
002868 Average Weekly Movement | 7.8% |
Biotechs Industry Average Movement | 5.6% |
Market Average Movement | 5.7% |
10% most volatile stocks in CN Market | 9.0% |
10% least volatile stocks in CN Market | 3.8% |
Stable Share Price: 002868's share price has been volatile over the past 3 months.
Volatility Over Time: 002868's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2003 | 992 | Tanping Lai | www.pclifecome.com |
Lifecome Biochemistry Co.,Ltd. operates as a biopharmaceutical company in China. It offers bacitracin zinc products, colistin sulfate products, probiotics products, bacitracin methylene disalicylate products, biological preservatives, etc.; veterinary drugs; and food preservatives.
Lifecome Biochemistry Co.,Ltd. Fundamentals Summary
002868 fundamental statistics | |
---|---|
Market cap | CN¥2.08b |
Earnings (TTM) | -CN¥243.02m |
Revenue (TTM) | CN¥567.21m |
3.6x
P/S Ratio-8.5x
P/E RatioIs 002868 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
002868 income statement (TTM) | |
---|---|
Revenue | CN¥567.21m |
Cost of Revenue | CN¥671.64m |
Gross Profit | -CN¥104.43m |
Other Expenses | CN¥138.59m |
Earnings | -CN¥243.02m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 29, 2024
Earnings per share (EPS) | -1.56 |
Gross Margin | -18.41% |
Net Profit Margin | -42.84% |
Debt/Equity Ratio | 233.6% |
How did 002868 perform over the long term?
See historical performance and comparison